Freestone Grove Partners LP
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 2007591
San Francisco, CA
Position in REGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$23,662,100
-$8,300,264 QoQ
Shares Held
30,625
-26.0% QoQ
Ownership
0.030%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Freestone Grove Partners LP holds $121,397,798 across 51 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
339,967 | $26,955,983 | |
| 2 | BMRN |
Biomarin Pharmaceutical Inc
|
364,194 | $20,839,180 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
64,813 | $12,138,178 | |
| 4 | CYTK |
Cytokinetics Inc
|
114,824 | $9,781,856 | |
| 5 | CELC |
Celcuity Inc.
|
67,907 | $7,104,430 | |
| 6 | MPLT |
MapLight Therapeutics, Inc.
|
168,912 | $6,053,806 | |
| 7 | ANL |
Adlai Nortye Ltd.
|
397,446 | $4,570,629 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
68,389 | $4,304,403 |
All Filings in REGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $23,662,100 | 30,625 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $31,962,364 | 41,409 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $36,114,039 | 64,229 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $22,790,775 | 43,411 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||